Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine
Authors:
- 1 January 2001
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 20 (1) , 25-33
Abstract
Aim. To study the ability of seven-valent experimental pneumococcal polysaccharide CRM197 protein conjugate vaccine (PncCRM) to induce antibodies in serum and saliva of infants. Methods. Sixty Finnish infants received PncCRM vaccine at 2, 4 and 6 months of age and were boosted with PncCRM (n = 30) or pneumococcal polysaccharide (PncPS) (n = 29) vaccine at the age of 15 months. Serum IgG antibody concentrations to vaccine serotypes 4, 6B, 9V, 14, 18C, 19F and 23F were measured by enzyme immunoassay at 2, 4, 6, 7, 15, 16 and 24 months of age. Salivary IgA, IgG and secretory Ig antibody titers at 7 and 16 months of ages were analyzed by enzyme immunoassay against the same serotypes, except 23F. Results. PncCRM induced systemic immune responses and immunologic memory. At 7 months of age 69 to 100% of children, depending on the serotype, had serum IgG antibody concentrations exceeding the value of 1.0 μg/ml. At 15 months the titers were still higher than before the vaccinations. Booster doses of either PncPS or PncCRM induced an increase in antibody concentrations. The titers were still elevated at 24 months of age. Salivary IgA and IgG antibodies were found rarely at 7 months of age, but in up to 80% of samples taken at 16 months of age, depending on the serotype and nature of the booster vaccine. Salivary IgG correlated with IgG in serum, supporting the theory that salivary IgG is derived from serum. Salivary IgA and secretory Ig correlated positively, which indicates that IgA was locally produced. Conclusions. PncCRM induces both systemic and mucosal immune responses in infants.Keywords
This publication has 40 references indexed in Scilit:
- Primary and Booster Salivary Antibody Responses to a 7‐Valent Pneumococcal Conjugate Vaccine in InfantsThe Journal of Infectious Diseases, 2000
- Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid1Presented in part at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995 and the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 1996.1Vaccine, 1999
- Mechanism of Antibody-Mediated Reduction of Nasopharyngeal Colonization by Haemophilus influenzae Type b Studied in an Infant Rat ModelThe Journal of Infectious Diseases, 1996
- Immunogenicity of heptavalent pneumococcal conjugate vaccine in infantsThe Journal of Pediatrics, 1996
- Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infantsThe Pediatric Infectious Disease Journal, 1996
- Immunogenicity and Efficacy of Streptococcus pneumoniae Polysaccharide-Protein Conjugate Vaccines against Homologous and Heterologous Serotypes in the Chinchilla Otitis Media ModelThe Journal of Infectious Diseases, 1996
- Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzas type b conjugate vaccinesThe Pediatric Infectious Disease Journal, 1995
- Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk childrenThe Journal of Pediatrics, 1993
- Anti-Capsular Polysaccharide Antibodies Reduce Nasopharyngeal Colonization byHaemophilus influenzaeType b in Infant RatsThe Journal of Infectious Diseases, 1993
- Quantitation of IgA in Human Whole SalivaActa Odontologica Scandinavica, 1981